Exelixis raises $71.8 million through stock offering

South San Francisco-based biotechnology company Exelixis Inc. (EXEL) said it has netted approximately $71.8 million through its public offering of 7 million shares of common stock.

Underwriter Goldman, Sachs & Co. has also been granted a 30-day option to purchase up to an additional 1.05 million shares of common stock.

If you find our journalism valuable and relevant, please consider joining our Examiner membership program.
Find out more at www.sfexaminer.com/join/

Just Posted

Boudin halts prosecution of man shot by police in Mission

Newly elected District Attorney Chesa Boudin has withdrawn the criminal complaint against… Continue reading

‘Mad Mob’ aims to influence SF City Hall on mental health policies

They are fed up with City Hall telling those who need the services what’s best for them

‘Trump chicken returns to SF Bay with new companion

The Trump Chicken will return to San Francisco Bay on Saturday, but… Continue reading

Police efforts to stem 49ers revelry in Mission District spark backlash

SFPD preparing for potential bonfires, vandalism on Super Bowl Sunday

Calendar of Events: San Francisco celebrates the Year of the Rat

JAN. 25 Choy Sun Doe Day: The San Francisco Chinese Chamber of… Continue reading

Most Read